China Biosimilars Market - Premium Insight, Industry Trends, FPNV Positioning Matrix, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2024 (Q4 2018 Update)


    Table of Contents

      1. Preface

      • 1.1. Objectives of the Study
      • 1.2. Market Segmentation & Coverage
      • 1.3. Years Considered for the Study
      • 1.4. Currency & Pricing
      • 1.5. Stakeholders

      2. Research & Forecasting

      • 2.1. Research Methodology
        • 2.1.1. Research Instruments
          • 2.1.1.1. Secondary Instrument
          • 2.1.1.2. Primary Instrument
        • 2.1.2. Research Approaches
          • 2.1.2.1. Bottom-up Approach
          • 2.1.2.2. Top-down Approach
        • 2.1.3. Research Reliability & Validity
        • 2.1.4. Research Assumptions
        • 2.1.5. Vendor Inclusion Criteria
      • 2.2. Forecasting Methodology
        • 2.2.1. Methodology for Market Estimation & Forecasting
        • 2.2.2. Significance and Importance of the Market Estimation & Forecasting

      3. Executive Summary

        4. Premium Insight

        • 4.1. Market Connectivity
        • 4.2. Market Data Feed
        • 4.3. Market Vendor Ranking Analysis
        • 4.4. Market Dynamics
          • 4.4.1. Drivers
          • 4.4.2. Restraints
          • 4.4.3. Opportunities
          • 4.4.4. Challenges
        • 4.5. Porter’s Five Forces Analysis
          • 4.5.1. Threat of New Entrants
          • 4.5.2. Threat of Substitutes
          • 4.5.3. Bargaining Power of Customers
          • 4.5.4. Bargaining Power of Suppliers
          • 4.5.5. Industry Rivalry
        • 4.6. CFDA Guidelines

        5. China Biosimilars Market, by Indication

        • 5.1. Introduction
        • 5.2. Autoimmune Diseases
        • 5.3. Blood Disorders
        • 5.4. Chronic Diseases
        • 5.5. Growth Hormone Deficiency
        • 5.6. Infectious Diseases
        • 5.7. Oncology

        6. China Biosimilars Market, by Manufacturing

        • 6.1. Introduction
        • 6.2. Contract Manufacturing
        • 6.3. In-House Manufacturing

        7. China Biosimilars Market, by Product

        • 7.1. Introduction
        • 7.2. Recombinant Glycosylated Proteins
          • 7.2.1. Erythropoietin (EPO)
          • 7.2.2. Follitropin
          • 7.2.3. Monoclonal Antibodies (MABS)
            • 7.2.3.1. Adalimumab
            • 7.2.3.2. Infliximab
            • 7.2.3.3. Rituximab
        • 7.3. Recombinant Non-Glycosylated Proteins
          • 7.3.1. Granulocyte Colony-Stimulating Factor (Filgrastim)
          • 7.3.2. Insulin
          • 7.3.3. Interferons
            • 7.3.3.1. Interferon-Alpha
            • 7.3.3.2. Interferon-Beta
          • 7.3.4. Recombinant Human Growth Hormone (RHGH)
        • 7.4. Recombinant Peptides
          • 7.4.1. Calcitonin
          • 7.4.2. Glucagon

        8. 360iResearch Competitive Strategic Window

        • 8.1. Introduction
          • 8.1.1. Leverage Zone
          • 8.1.2. Vantage Zone
          • 8.1.3. Speculative Zone
          • 8.1.4. Bottleneck Zone

        9. 360iResearch FPNV Positioning Matrix

        • 9.1. Introduction
        • 9.2. 360iResearch Scores
          • 9.2.1. Forefront
          • 9.2.2. Pathfinders
          • 9.2.3. Niche
          • 9.2.4. Vital
        • 9.3. Business Strategy
        • 9.4. Product Satisfaction

        10. Competitive News Feed Analysis

          11. Company Usability Profiles

          • 11.1. 3SBio Inc.
          • 11.2. APOGENIX GmbH
          • 11.3. AbbVie Inc.
          • 11.4. Akeso Biopharma, Inc.
          • 11.5. Amgen Inc.
          • 11.6. BeiGene Ltd
          • 11.7. Biogen Inc.
          • 11.8. Bristol-Myers Squibb Pharmaceuticals Limited
          • 11.9. Genexine, Inc.,
          • 11.10. InflaRx N.V.
          • 11.11. Innovent Biologics, Inc.
          • 11.12. Janssen Pharmaceuticals, Inc.
          • 11.13. Merck Sharp & Dohme Corp.
          • 11.14. Pfizer Inc.
          • 11.15. Roche Holding AG
          • 11.16. Shanghai Junshi Biosciences Co., Ltd.

          12. Appendix

          • 12.1. Top Reports
          • 12.2. Author Details

          LIST OF TABLES (11 TABLES)

            TABLE 1. CHINA BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD BILLION)

              TABLE 2. CHINA BIOSIMILARS MARKET RANKING, BY VENDORS, 2017

                TABLE 3. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2016 - 2024 (USD BILLION)

                  TABLE 4. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2016 - 2024 (USD BILLION)

                    TABLE 5. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD BILLION)

                      TABLE 6. 360IRESEARCH SCORES FOR FOREFRONT IN BIOSIMILARS MARKET

                        TABLE 7. 360IRESEARCH SCORES FOR PATHFINDERS IN BIOSIMILARS MARKET

                          TABLE 8. 360IRESEARCH SCORES FOR NICHE IN BIOSIMILARS MARKET

                            TABLE 9. 360IRESEARCH SCORES FOR VITAL IN BIOSIMILARS MARKET

                              TABLE 10. 360IRESEARCH FPNV POSITIONING MATRIX BUSINESS STRATEGY FOR BIOSIMILARS MARKET

                                TABLE 11. 360IRESEARCH FPNV POSITIONING MATRIX PRODUCT SATISFACTION FOR BIOSIMILARS MARKET

                                  LIST OF FIGURES (18 TABLES)

                                    FIGURE 1. CHINA BIOSIMILARS MARKET: YEARS CONSIDERED FOR THE STUDY

                                      FIGURE 2. CHINA BIOSIMILARS MARKET: KEY RESEARCH METHODOLOGY

                                        FIGURE 3. CHINA BIOSIMILARS MARKET: KEY RESEARCH INSTRUMENTS

                                          FIGURE 4. CHINA BIOSIMILARS MARKET: KEY SECONDARY INSTRUMENT SOURCES

                                            FIGURE 5. CHINA BIOSIMILARS MARKET: KEY POTENTIAL RESPONDENTS

                                              FIGURE 6. CHINA BIOSIMILARS MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT

                                                FIGURE 7. CHINA BIOSIMILARS MARKET: KEY RESEARCH APPROACHES

                                                  FIGURE 8. CHINA BIOSIMILARS MARKET: KEY DATA TRIANGULATION

                                                    FIGURE 9. CHINA BIOSIMILARS MARKET: KEY RESEARCH ASSUMPTIONS

                                                      FIGURE 10. BIOSIMILARS MARKET: KEY MARKET CONNECTIVITY

                                                        FIGURE 11. CHINA BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD BILLION)

                                                          FIGURE 12. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2017 VS 2024 (USD BILLION)

                                                            FIGURE 13. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2017 VS 2024 (USD BILLION)

                                                              FIGURE 14. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD BILLION)

                                                                FIGURE 15. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR CHINA BIOSIMILARS MARKET, BY INDICATION, 2024

                                                                  FIGURE 16. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR CHINA BIOSIMILARS MARKET, BY MANUFACTURING, 2024

                                                                    FIGURE 17. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR CHINA BIOSIMILARS MARKET, BY PRODUCT, 2024

                                                                      FIGURE 18. 360IRESEARCH FPNV POSITIONING MATRIX FOR BIOSIMILARS MARKET

                                                                      The china biosimilars market is expected to grow from USD 0.93 billion 2017 to USD 7.12 billion by the end of 2024, at a Compound Annual Growth Rate (CAGR) of 33.79%.

                                                                      Market Segmentation & Coverage: The report on china biosimilars market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the economies and geographies of the potential customer group can help to gain business acumen for better strategic decision making. Our market coverage across different industry verticals reveals the hidden truth about the strategies adopted by the players in different verticals and help the organization to decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.This research report categorizes the china biosimilars market to forecast the revenues and analyze the trends in each of the following sub-markets:

                                                                      Based on Indication
                                                                      1. Autoimmune Diseases
                                                                      2. Blood Disorders
                                                                      3. Chronic Diseases
                                                                      4. Growth Hormone Deficiency
                                                                      5. Infectious Diseases
                                                                      6. Oncology

                                                                      Based on Manufacturing
                                                                      1. Contract Manufacturing
                                                                      2. In-House Manufacturing

                                                                      Based on Product
                                                                      1. Recombinant Glycosylated Proteins
                                                                      2. Recombinant Non-Glycosylated Proteins
                                                                      3. Recombinant Peptides

                                                                      Company Usability Profiles:
                                                                      The biosimilars market research report provides the company usability profiles and analyze the business overview, business product offering, SWOT analysis, and business strategy of the following company:
                                                                      1. 3SBio Inc.
                                                                      2. APOGENIX GmbH
                                                                      3. AbbVie Inc.
                                                                      4. Akeso Biopharma, Inc.
                                                                      5. Amgen Inc.
                                                                      6. BeiGene Ltd
                                                                      7. Biogen Inc.
                                                                      8. Bristol-Myers Squibb Pharmaceuticals Limited
                                                                      9. Genexine, Inc.,
                                                                      10. InflaRx N.V.
                                                                      11. Innovent Biologics, Inc.
                                                                      12. Janssen Pharmaceuticals, Inc.
                                                                      13. Merck Sharp & Dohme Corp.
                                                                      14. Pfizer Inc.
                                                                      15. Roche Holding AG
                                                                      16. Shanghai Junshi Biosciences Co., Ltd.

                                                                      Research Methodology:
                                                                      Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

                                                                      Reasons to Buy:
                                                                      1. To comprehensively understand of the biosimilars market with respect to major influencing factor such as drivers, restraints, opportunities and challenges
                                                                      2. To strategically analyze each vertical and geographic sub-segment in the biosimilars market and its individual growth and its impact towards the growth of overall market
                                                                      3. To position selected vendors in 360iResearch FPNV Positioning Matrix for the biosimilars market to uncover a competitive landscape based on business strategy and product satisfaction



                                                                      Summary:
                                                                      China Biosimilars Market Research Report is about China Biosimilars Industry study. Get complete China Biosimilars market research report published after Market Study, Industrial Analysis with Trends & Statistics. China Biosimilars Market Report is a syndicated report for Investors and Manufacturer to understand Market Demand, Growth, trends and Factor Influencing market in upcoming years.



                                                                      REPORT YOU MIGHT BE INTERESTED